Highlights Newsletter 4

This newsletter presents you the following key sessions:

1. Podcast with Prof. Dr. Radford about improved overall survival with first-line brentuximab vedotin plus
    chemotherapy in patients with stage III/IV classical Hodgkin lymphoma

2. Long-term remission rates after treatment with tisagenlecleucel in paediatric and young adult patients with
    R/R B-ALL

3. Matched propensity scoring suggests a higher efficacy, with increased toxicity for axicabtagene ciloleucel vs.
    tisagenlecleucel in the treatment of relapsed/refractory diffuse-large B-cell lymphoma

4. Erythropoietin stimulation agents significantly improve outcome in lower-risk myelodysplastic syndrome

5. Superior PFS with extended KRd versus standard lenalidomide maintenance after stem cell transplant for multiple
    myeloma